Top Markets
Coin of the day
Cardiol Therapeutics Inc. Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc.

CRDL
Rang in Aktien #17188
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company,... Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
Aktienkurs
$2.17
Marktkapitalisierung
$249.58M
Veränderung (1 Tag)
-1.67%
Veränderung (1 Jahr)
96.34%
Land
CA
Handel Cardiol Therapeutics Inc. (CRDL)

Kategorie

P/S-Verhältnis für Cardiol Therapeutics Inc. (CRDL)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Cardiol Therapeutics Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Cardiol Therapeutics Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber